Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 773 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metformin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02077803
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Results available

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

NCT02515773
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Metformin, healthy lifestyle intervention (LIFE)
Drug · Behavioral
Lead sponsor
Melissa Delbello
Other
Eligibility
8 Years to 19 Years
Enrollment
1,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
29
States / cities
Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 22, 2026, 8:22 AM EDT
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome

NCT03355469
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Metformin, Placebo, Low Intensity Exercise, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers University
Other
Eligibility
40 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Early Phase 1 Interventional

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

NCT03618654
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions
Metformin, Durvalumab
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00707031
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

NCT01068743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

NCT02220218
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Early Phase 1 Interventional

Fetal Hemoglobin Induction Treatment Metformin

NCT02981329
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
Interventions
Metformin, Questionnaires
Drug · Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of BMS-986165 on the Blood Levels of Metformin

NCT04671953
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

NCT03317028
View directory record Official record
Conditions
T2DM With Inadequate Glycemic Control
Interventions
CS02 tablet and placebo tablet
Drug
Lead sponsor
Center Laboratories, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Little Rock, Arkansas • Coral Gables, Florida • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 22, 2026, 8:22 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

NCT01496430
View directory record Official record
Conditions
Hypertension, Diabetes
Interventions
Placebo, Azilsartan medoxomil
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
68
States / cities
Birmingham, Alabama • Green Valley, Arizona • Tempe, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 8:22 AM EDT
Recruiting Phase 3 Interventional

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

NCT06763328
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Riverside, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 22, 2026, 8:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer

NCT06030622
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin), C3 (Metformin, Simvastatin, and Digoxin) only
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 22, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 22, 2026, 8:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

NCT02581137
View directory record Official record
Conditions
Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
Interventions
Laboratory Biomarker Analysis, Metformin Hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 22, 2026, 8:22 AM EDT